Cookies are used on this website

Cookies are used to improve your browsing experience on Radiometer websites. No personally identifiable information is stored or used.

Don't show this message againRead more about cookies

Thursday, September 09, 2010

Register for free webinar: The importance of troponin testing at the point of care

European Society of Cardiology and American College of Cardiology guidelines point to troponin as the most definitive method of acute myocardial infarction (AMI) detection. A turnaround time of less than 60 minutes is recommended for diagnosing AMI, driving an increased focus on testing the parameter at the point of care.

European Society of Cardiology and American College of Cardiology guidelines point to troponin as the most definitive method of acute myocardial infarction (AMI) detection. A turnaround time of less than 60 minutes is recommended for diagnosing AMI, driving an increased focus on testing the parameter at the point of care.

Therefore, Radiometer and acutecaretesting.org are sponsoring the webinar The importance of troponin testing at the point of care with Dr Jan Ravkilde from the. The webinar will be held on September 28, 2010, 1:00 - 2:00 PM Central European Time.

The webinar is free. Register here

Better diagnosis of AMI by measuring troponin at the point of care
Guidelines advocate a turn-around-time of less than 60 minutes in diagnosing acute coronary syndrome (ACS). Performing troponin measurements in the hospital’s central lab can take considerable valuable time before results are reported to the clinicians. At the point of care, troponin testing is extremely accurate and available in 20 minutes. Faster analysis leads to more immediate treatment resulting in significantly improved patient outcome. In addition, if troponin tests rule out AMI, faster test results can shorten patients’ length of stay, which substantially increases hospital efficiency.

In this webinar, Dr. Ravkilde will discuss the current state of AMI diagnosis using the troponin biomarker, and review the recent advances that have led to such improved accuracy and speed in its measurement at the point of care.

About the presenter
Jan Ravkilde, MD, DMSc, FESC, FACC is an Associate Professor, Chief Physician and the Head of the Cardiology Invasive Section in the Department of Cardiology, Heart Center Aalborg, at Aarhus University Hospital in Aalborg, Denmark. He has been awarded Gold prize dissertations and is a fellow of both the European Society of Cardiology and the American College of Cardiology.

As Head of Clinical Cardiology Research at Aarhus University Hospital, Dr. Ravkilde has conducted numerous study visits to Research Centers of Cardiology, Thoracic Surgery, and Clinical Biochemistry in Europe and United States. A frequent Lecturer and invited speaker at various international congresses, courses and symposia, Dr. Ravkilde has performed more than 8500 heart catheterizations, percutaneous coronary interventions, and right heart catheterizations. He has authored both cardiology books and more than 80 articles in peer-reviewed international Journals.

For a recent article by Dr. Ravkilde on cardiac biomarkers, visit:
http://acutecaretesting.org/cardiac-biomarkers

This webinar will:
Present guidelines for troponin testing turnaround time and differentiate between central lab and point of care measurement time and accuracy.
Differentiate between the troponin T and troponin I and compare their effectiveness as cardiac biomarkers.
Discuss the advancements made from fourth generation to fifth generation troponin T testing Review the new universal definition of MI, especially type 2 MI.
Highlight the importance of serial measurements in diagnosing AMI in accordance with guidelines.
Investigate controversies and conflicts surrounding screening programs for contrast-induced nephropathy.

Who should attend?
Cardiologists, hospital laboratorians, point-of-care coordinators, emergency physicians and critical care clinicians.

Attendance is limited - Register today